AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02136992 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: placebo will be taken two tablets 3 times a day during the whole study process
Study NCT02136992 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo will be taken two tablets 3 times a day during the whole study process
Study NCT01502527 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Femarelle
Description: Twice daily oral treatment with Femarelle
Study NCT04053504 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Teamwork-Peer Delivery
Description: Children with T1D and their parent will participate in 6 in-person FT-P group sessions during a 12-month period. Parents will also participate in monthly telephone support calls with a Parent Leader during the 12-month intervention period.
Study NCT00153231 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IVS
Description: Infracoccygeal sacropexy
Study NCT02429427 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two capsules once daily with food
Study NCT00782925 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: educational program
Description: Educational program will consist of 1, 2-hour, small-group (8-patient) session with a specialist physician in Physical and Rehablilitation Medecine. Workers will be given information about lower back pain, pain and psychosocial risk factors for persistent or recurrent back-related disability
Study NCT04233463 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide
Description: Standard treatment for mild Crohn Disease patients
Study NCT02436252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DSP-7888
Description: 3.5-10.5 mg/body,Id every 2-4 weeks
Study NCT00782925 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise program
Description: The exercise program will consist of 5, 90-minute, small-group (8-patient) sessions with a physical therapist. Healthcare workers will be taught exercises including warm-ups, floor exercises, and endurance training. Only one absence will be allowed, otherwise the worker will be considered as non-compliant.
Study NCT00782925 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-led exercises
Description: Self-led exercises to perform as part of a daily exercise routine
Study NCT03919253 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: pyrotinib maleate tablets+nab-paclitaxel
Description: pyrotinib maleate tablets: 400mg orally once daily continunously nab-paclitaxel: 125mg/m2 iv d1、8 of each 21 day cycle, 6cycles.
Study NCT03251014 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: YSS
Description: Intervention providing steamed whole YSS (\~265 g/day, 3 days/week) for eight weeks
Study NCT03251014 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Salmon
Description: Intervention providing steamed salmon fillet (\~246 g/day, 3 days/week) for eight weeks
Study NCT00292474 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: percutaneous coronary intervention
Study NCT00292474 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: percutaneous coronary intervention
Study NCT02956174 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Co-Cr single crown
Study NCT02956174 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Periodontal parameters
Study NCT02956174 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Periodontal parameters
Study NCT03823937 — intervention group
Intervention type: OTHER
Intervention: Sniffin' Sticks test and Taste strips
Description: Sniffin' Sticks test (Burghardt®, Wedel, Germany) is a psychophysical test. It allows semi-objective assessment of the patient's olfactory performance by means of 3 subtests: threshold test, identification test and discrimination test. The Sniffin' Sticks Olfactory Test Kits contain pen like bodies as, for example, in pens used to write on flipcharts or whiteboards.These pen-like bodies, however, contain a fibre stick which is filled with scents. For testing, the cap should be removed so the patient can smell on the tip of the pen.~The taste strips are a validated examination procedure to investigate the taste ability. When testing the whole mouth taste ability, the taste strips are applied by putting them on the tongue and closing the mouth.
Study NCT04250298 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: sucrosomal iron
Description: oral intake of iron as sachets or capsules
Study NCT03075397 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: blood sample
Description: A sample of HIV-1 infected patients's blood is collected
Study NCT03075397 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: sperm sample
Description: A sample of HIV-1 infected patients's sperm is collected
Study NCT00153231 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sacrospinofixation
Study NCT01550510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbic Acid
Description: 3x a week for 9 weeks
Study NCT01550510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 350mg/m2 once a week every 3 weeks
Study NCT01550510 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: 350mg/m2 once a week every 3 weeks
Study NCT01582581 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telephonic CBT
Description: Cognitive behavioral therapy, guided by computer, using the TAD protocol for treatment of Adolescent Depression, modified for delivery by a nurse or master's level clinician over the telephone in 15-18 sessions lasting 30-45 minutes at weekly intervals. Includes regular and standardized weekly monitoring by the treating clinician of depressive symptoms and factors affecting suicide risk.
Study NCT01582581 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Wait List Control
Description: Wait list control with measurement of key outcomes at baseline (week 0), and then weeks 3 and 5.
Study NCT03770702 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Angiotensin receptor blockers
Description: Candesartan
Study NCT01030068 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga
Description: Yoga twice weekly
Study NCT01030068 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Wellness
Description: Health and wellness classes twice weekly
Study NCT03770702 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Statins
Description: Atorvastatin
Study NCT03482232 — intervention group
Intervention type: DRUG
Intervention: Benzodiazepines
Description: Benzodiazepines for insomnia, agitation or delirium in people older than 65
Study NCT03482232 — intervention group
Intervention type: DRUG
Intervention: Non-steroidal anti-inflammatory drugs
Description: Non-steroidal anti-inflammatory drugs in patients with cardiovascular disease, chronic kidney disease, hypertension, heart failure or liver cirrhosis
Study NCT03482232 — intervention group
Intervention type: DRUG
Intervention: paracetamol
Description: paracetamol 1g for more than 3 days
Study NCT03482232 — intervention group
Intervention type: DRUG
Intervention: Antimicrobial agent
Description: antibiotic in acute bronchitis when the patient does not suffer from COPD, heart failure, diabetes or kidney disease or is undergoing active chemotherapy
Study NCT03482232 — intervention group
Intervention type: DRUG
Intervention: Lipid-lowering drug
Description: Lipid-lowering drugs in patients older than 75 years without previous cardiovascular events
Study NCT03482232 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Prostate cancer
Description: Screening for prostate cancer in asymptomatic patients
Study NCT01030068 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Smoking cessation therapy
Description: Smoking cessation therapy
Study NCT01030068 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Smoking cessation therapy
Description: Smoking cessation therapy
Study NCT03482232 — intervention group
Intervention type: RADIATION
Intervention: Lumbago
Description: image tests in non-specific lumbago
Study NCT03482232 — intervention group
Intervention type: DRUG
Intervention: Antimicrobial agent
Description: antibiotics for pharyngitis (infants)
Study NCT03482232 — intervention group
Intervention type: DRUG
Intervention: Mucolytic
Description: mucolytics, antitussives or antibiotics for upper respiratory infections (infants)
Study NCT03482232 — intervention group
Intervention type: DRUG
Intervention: Ibuprofen and paracetamol
Description: treatment with ibuprofen and paracetamol (infants)
Study NCT01554709 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aortic Cannulas (CardioGard)
Description: Comparison of aortic cannulas during by pass surgery
Study NCT00938327 — intervention group
Intervention type: BIOLOGICAL
Intervention: Rotarix™
Description: Two doses of oral vaccine.
Study NCT01554709 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Aortic Cannulas (CardioGard)
Description: Comparison of aortic cannulas during by pass surgery
Study NCT00814983 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Naive T-cell Depleted Stem Cell Transplant
Description: The Isolex device from Baxter will be used to perform the cell selection procedure. After the CD34 selected stem cell graft has been collected, the CD34- flow-throughfraction will be depleted of CD45RA+ naive T-cells. To accomplish this, a second immunomagnetic bead selection process will be performed on the Isolex device, making use of a GMP-grade murine anti-human CE45RA antibody. This depleted fraction will comprise the donor lymphocyte inoculum given to the transplant recipient along with the stem cell component on day 0 of transplant.
Study NCT00814983 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stem Cell Transplant No Manipulation
Description: These patients will be transplanted with unmanipulated peripheral blood stem cells.
Study NCT00814983 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Isolex device from Baxter
Study NCT04398225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Centanafadine
Description: Extended release capsule
Study NCT02174770 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood Flow Restriction (BFR) Training
Description: This is a modality of physical therapy where during low-load resistance activity, the venous return of blood from an extremity is limited only during the duration of the exercise. This can be accomplished through multiple means. For the purposes of our study, we will use an inflatable tourniquet.
Study NCT01874743 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20 mg/day
Description: All patients must take 20mg/day of rosavastatin during 3 months
Study NCT01593189 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: KITS Program
Description: This is a 4-month psychosocial intervention for children with developmental disabilities and behavior problems who are entering kindergarten and their caregivers. The intervention begins in the summer before kindergarten. The KITS intervention consists of: (a) child school readiness play groups to facilitate the development of self-regulatory, social, and early literacy skills (2 times per week in summer, 1 times per week in the fall); and (b) a bi-monthly psychoeducational support group to promote parent involvement in the child's early literacy and schooling and the use of effective parenting techniques
Study NCT02174770 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood Flow Restriction (BFR) Training
Description: This is a modality of physical therapy where during low-load resistance activity, the venous return of blood from an extremity is limited only during the duration of the exercise. This can be accomplished through multiple means. For the purposes of our study, we will use an inflatable tourniquet.
Study NCT02174770 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard ACSM-guided strength training
Description: This is the standard protocol to be used for post-operative and other physical therapy patients for rehabilitation. It includes the use of American College of Sports Medicine-guidelines for how much weight to use during the strength training portion of the rehabilitation.
Study NCT02174770 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard ACSM-guided strength training
Description: This is the standard protocol to be used for post-operative and other physical therapy patients for rehabilitation. It includes the use of American College of Sports Medicine-guidelines for how much weight to use during the strength training portion of the rehabilitation.
Study NCT01424137 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Easyhaler type A
Description: Easyhaler type A inhaler, 3 consecutive inhalations
Study NCT01424137 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Easyhaler type B
Description: Easyhaler type B inhaler, 3 consecutive inhalations
Study NCT01424137 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Diskus inhaler
Description: Diskus inhaler, 3 consecutive inhalations
Study NCT00595465 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Japanese Encephalitis purified inactivated vaccine
Description: IC51 6 mcg i.m. injection on Day 0 and Day 28
Study NCT02559856 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apixaban
Study NCT02559856 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivaroxaban
Study NCT01355666 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DermaTherapy® Linen and underpads.
Description: DermaTherapy® Linen is a 100% synthetic silk-like fabric technology designed to provide a cleaner, drier and smoother surface between the skin and support systems for a healthy micro-climate.~Subjects in the DermaTherapy® Linen Group are compared to subjects receiving usual care - bed linen made of cotton-blend fabrics.
Study NCT04280380 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Real time PCR
Description: At inclusion, serum samples will be collected to determine CMV serological status. Plasma samples will be collected weekly for CMV PCR analysis. Antibodies for CMV will be assessed using a commercial enzyme immunoassay kit for detection of total antibodies to CMV (LIAISON CMV IgG assay, DiaSorin S.p.A). DNA will be extracted in 200 μL of plasma eluted in 60 μL of elution buffer using a NucliSENS easyMAG system (bioMérieux, Boxtel, The Netherlands). Samples will be amplified using Affigene CMV Trender diagnostic assay (Cepheid AB, Bromma, Sweden), according to the manufacturer instructions. Amplification will be performed on a MX3000P instrument (Stratagene Instruments Systems, La Jolla, CA, USA). Samples with >500 copies/mL of plasma will be considered positive.
Study NCT04507100 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: World Health Organization Health Promoting Schools
Description: Healthy eating: regulation and monitoring of food sold in school cafeterias, healthy eating behavior change campaign, provision of healthy breakfasts.~Physical activity: hourly active breaks during classes, quality physical education, active recess, and extra-curricular leisure activities and tournaments.~Healthy hydration: access to water fountains and regular monitoring of water safety, regulation and monitoring of beverages sold in the school, and social marketing campaign promoting drinking plain water.~Other cross-sectional activities: Referral of children identified as living with underweight, overweight, or obesity, training for school directors, teachers and parents, establishment of school objectives to become a health promoting school, monitoring progress, and publicly acknowledging school progress in becoming a health promoting school.
Study NCT01298531 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: etanercept
Description: etanercept 50 mg subcutaneous (SC) injections once weekly for 16 weeks.
Study NCT01298531 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: etanercept
Description: etanercept 50 mg subcutaneous (SC) injections once weekly for 8 weeks following the prior 8 weeks of placebo.
Study NCT01298531 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo subcutaneous (SC) injections once weekly for 8 weeks.
Study NCT03487523 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Text Message
Description: As already stated
Study NCT03326726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2% CHG
Description: Chlorhexidine Gluconate
Study NCT04342273 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KW-6356
Description: KW-6356 will be administered once daily as therapeutic at Day 1 through Day 7
Study NCT04342273 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KW-6356
Description: KW-6356 will be administered once daily as supratherapeutic dose at Day 1 through Day 7
Study NCT04342273 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered once daily at Day 1 through Day 7
Study NCT04342273 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: Placebo will be administered once daily at Day 1 through Day 6, followed by Moxifloxacin once daily at Day 7.
Study NCT00632840 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin and fenofibrate
Description: atorvastatin (40mg/day) fenofibrate (200mg/day)
Study NCT00632840 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atorvastatin and fenofibrate
Description: atorvastatin (40mg/day) fenofibrate (200mg/day)
Study NCT00967252 — intervention group
Intervention type: DRUG
Intervention: Atorvastatin
Description: Atorvastatin 10 mg daily or equivalent dose in another statin
Study NCT00967252 — intervention group
Intervention type: DRUG
Intervention: Atorvastatin
Description: Atorvastatin 20 mg daily or equivalent dose in another statin
Study NCT00967252 — intervention group
Intervention type: DRUG
Intervention: Atorvastatin
Description: Atorvastatin 40 mg daily or equivalent dose in another statin
Study NCT00910702 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: foldable capsular vitreous body(FCVB)
Description: the vitreous cavity is tamponaded with the foldable capsular vitreous body (FCVB) after PPV
Study NCT02883582 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: oxyhydrogen
Description: Hydrogen/oxygen mixed gas inhaled(proportion 2:1),3 L/min . 1 hour each time,twice a day(BID).Test Duration is three months.
Study NCT02883582 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: oxygen
Description: oxygen inhaled,3 L/min . 1 hour each time,twice a day(BID).Test Duration is three months.
Study NCT00884182 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: A/H5N1 Inactivated, Split Virion Pandemic Influenza Vaccine
Description: 0.5 mL, Intramuscular
Study NCT01921270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Dose - AbobotulinumtoxinA
Description: Participants will receive low dose AbobotulinumtoxinA injections. Location of injections will be determined by the clinician to treat the individual's dystonic symptom.~Muscles that may be included for in injection for OMD with Jaw Closing:~Medial Pterygoid 50 units, Masseter 25 units~Muscles that may be included in injection for OMD with Jaw Opening:~Lateral Pterygoid 50 units, Anterior digastrics 10 units~Muscle that will be included in injection for OMD with Tongue Protrusion:~Genioglossus 7.5 units
Study NCT04263662 — intervention group
Intervention type: OTHER
Intervention: Analgesia-Sedation algorithm
Description: The analgesia-sedation algorithm is a suggested protocol for approach to providing analgesia and sedation to patients admitted to the pediatric ICU who are newly intubated. The approach focuses on using dexmedetomidine as the primary sedative, non-opioids as the primary analgesia, then stepwise approach to adding in adjunctives (e.g. opioids, non-benzodiazepines) with the intention of minimizing benzodiazepine exposure and utilizing minimal-dose effective analgesia/sedative dosing.
Study NCT02512692 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SIR-Spheres microspheres (Yttrium-90 Microspheres)
Description: On Day 3 or 4 of cycle 1 90Y TARE will be administered
Study NCT02266498 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BIBB 515 BS
Study NCT02266498 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBB 515 BS
Study NCT02266498 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard breakfast (40 g fat)
Study NCT02242188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron
Description: Ferric pyrophosphate (powder preparation in sachets: Actiferol, SunActive Fe, Sequoia, Poland) in a single daily dose. Three doses will be used: 7 mg for infants up to 7 kg of body weight, 10 mg for infants from 7 to 10 kg of body weight, and 15 mg for those exceeding the weight of 10 kg. Caregivers will be instructed to administer the daily dose at the same time of a day, after mixing the content of the sachet with a little amount of breastmilk or milk formula.~The intervention will last from 4 months to 9 months of age.
Study NCT00967252 — intervention group
Intervention type: DRUG
Intervention: Atorvastatin
Description: Atorvastatin 80 mg daily or equivalent dose in another statin
Study NCT00967252 — intervention group
Intervention type: OTHER
Intervention: Control
Description: No statin being taken
Study NCT03751982 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Electrical Neuromodulation (TES)
Description: TES phase-aligned with slow waves or not
Study NCT02242188 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Maltodextrin (packed in identical sachets as active products)